Project description
Transitioning to new preventative healthcare
The You2Yourself company's mission is to eliminate late diagnoses via personalised health monitoring. The company aims to expand its value proposition from single disease diagnostics for the healthcare provider market to general health monitoring for the consumer market. To determine the feasibility of their technology in this field, the EU-funded U-MON project will focus on the study of panels of RNA molecules whose expression levels are linked to specific types of cancer. Then, using the panels, it will create a deconvolution algorithm able to predict the presence of these cancers in complex expression data. The performance of the algorithm will determine the feasibility of RNA profiling for general health monitoring.
Objective
Y2Y is a start-up company in molecular diagnostics. Y2Y develops methodology for early disease detection in body fluids and is building a biobank of longitudinal samples containing disease onset for this purpose. Y2Y aims to extend its value proposition from single disease diagnostics for the health care provider market, to general health monitoring for the consumer market. This is a disruptive transition from traditional reactive healthcare to new-preventive healthcare. To establish the potential of its technology for general health monitoring, Y2Y has phrased 2 objectives and needs a bio-informatician to perform the research to achieve these objectives.
The first goal will be to elucidate - by statistical analyses of public cancer tissue data - panels of small RNA molecules whose expression levels are associated with specific types of cancer.
The second goal is to use these panels for the AI-driven development of a deconvolution algorithm to predict the presence of specific types of cancer in complex expression data.
The performance of such an algorithm will indicate the potential of small RNA profiling for health monitoring and allow Y2Y to chose (or chose not) to invest in development of a health monitoring product.
Y2Y offers a tailored integration and education program to the associate that will result in skillsets in personalized medicine and biomarker development that will render the associate attractive to companies as well as academic groups in this field.
Fields of science
Programme(s)
Funding Scheme
CSA-LSP - Coordination and support action Lump sumCoordinator
7521 AN ENSCHEDE
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.